Here, we describe the mechanism of action of a third compound, Y102, and identify inhibition of lysosomal trafficking as a potential vulnerability of both sporadic and neurofibromatosis type I-associated NF1-deficient tumors. This evidence concerns the gene NF1 and neurofibromatosis type 1.